X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Cancer Discovery

期刊標題檢索 CANCER DISCOV 最新評論: There are differences here, not just looking at the impact factor. All... (2023-10-09)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Cancer Discovery]您好,您是該頁面的第 81002 位訪客。

期刊簡介
期刊名稱Cancer Discovery Cancer Discovery
LetPub Score
9.3
50 ratings
Rate

Reputation
10.0

Influence
9.3

Speed
7.0

期刊簡稱CANCER DISCOV
ISSN2159-8274
E-ISSN2159-8290
h-index119
CiteScore
CiteScoreSJRSNIPCiteScore Rank
22.907.5333.803
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q117 / 404

自引率 (2023-2024)1.00%自引率趨勢
掲載範囲
Cancer Discovery publishes high-impact, peer-reviewed articles describing major advances in research and clinical trials. As the premier cancer information resource, the Journal also presents Review Articles, Perspectives and Commentaries, News stories, and Research Watch summaries of important journal articles to its readers to keep them informed about the latest findings in the field. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic and epidemiologic studies
官方網站http://cancerdiscovery.aacrjournals.org/
在線稿件提交https://cd.msubmit.net/cgi-bin/main.plex
開放訪問No
出版商American Association for Cancer Research Inc.
主題領域ONCOLOGY
出版國/地區UNITED STATES
發行頻率
創刊年2011
每年文章數117每年文章數趨勢
黃金OA百分比36.96%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ18/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2159-8274%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Slow, 6-12 Week(s)
競爭力 *來自作者的數據: Very difficult
參考鏈接
相關期刊 【Cancer Discovery】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    NATURE REVIEWS DRUG DISCOVERYH-index: 289

    CiteScore: 137.40
    LANCETH-index: 700

    CiteScore: 148.10
    NEW ENGLAND JOURNAL OF MEDICINEH-index: 933

    CiteScore: 145.40
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    Nature Reviews Disease PrimersH-index: 48

    CiteScore: 76.70
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 93.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONH-index: 622

    CiteScore: 48.20
    World PsychiatryH-index: 70

    CiteScore: 64.10
    學科內最受檢索的期刊 頁面查看次數
    MEDICINE640959
    BIOMATERIALS574367
    BIOMEDICINE & PHARMACOTHERAPY498367
    Frontiers in Pharmacology487305
    JOURNAL OF ETHNOPHARMACOLOGY479368
    Journal of Materials Chemistry B476066
    Frontiers in Immunology458030
    COLLOIDS AND SURFACES B-BIOINTERFACES419246
    COMPUTERS IN BIOLOGY AND MEDICINE416597
    Frontiers in Oncology413506
  •  

    Cancer Discovery Cancer Discovery
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    下一頁    末頁  (頁
/2)
  [Cancer Discovery] 的評論撰寫評論
作者: Martha Jacob


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-09 09:17:52 評論於
There are differences here, not just looking at the impact factor.
All three journals are top level, there is no doubt about that.
It is said here that Cancer Cell is the big brother, mainly because of the contributions of big shots who are doing cancer research around it. Generally speaking, if an article has enough information, CC is usually the first choice.
Also, in terms of industry reputation, CC has been established for more than 20 years. Compared to Nature Cancer and Cancer Discovery, there is no doubt that it is the big brother. It has nothing to do with the impact factor, and even looking at IF, CC is currently the highest
(0) 讚! | Martha Jacob

作者: 是志丹吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-07 18:49:54 評論於
They should be similar, the three mainstream publications are also similar. Although the impact factor is different, it does not mean that one is better than the other! They are all top-notch. Just like the articles published in Science are not necessarily worse than in Nature, it is just that some authors prefer one over the other, and the article numbers are slightly different. They are all top-notch
(0) 讚! | 是志丹吖

作者: 太山嘉懿


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-07 16:14:11 評論於
Why are Impact Factors of Science and AACR so high (The editor is of Chinese descent)? Cell and Nature are both commercial, while Science and AACR have always maintained their academic independence
(0) 讚! | 太山嘉懿

作者: 是志丹吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-07 09:36:26 評論於
Cancer cells are also transitioning and starting to include clinical articles, which may lead to an increase in impact factor
(0) 讚! | 是志丹吖

作者: Martha Jacob


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-15 21:10:41 評論於
Magazines at this level, whether slightly higher or lower in impact factor, no longer make any difference
(0) 讚! | Martha Jacob

作者: Martha Jacob


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-13 21:07:38 評論於
Submission hit rate: 5.0
Sharing experience: It feels like Cancer Cell, Cancer Discovery, and Nature Cancer will form a tripartite alliance in the future. As of now, Cancer Cell remains the undisputed leader
(0) 讚! | Martha Jacob

作者: 重阳悦爱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-01 09:35:04 評論於
Review speed: 1.0 | Submission acceptance rate: 25.0 Emphasized research direction: Medical experience sharing: More focused on clinical aspects, not bad, but in comparison, there is a gap in article quality compared to Cancer Cell
(0) 讚! | 重阳悦爱

作者: mingq w


領域: 生物学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2023-04-16 23:58:15 評論於
Extremely authoritative journal
(1) 讚! | mingq w

作者: 血天谷云


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-01-09 23:18:51 評論於
22 years later, CC is ahead again. His pitch was rejected, so he tried his luck with CD
(0) 讚! | 血天谷云

作者: 血天谷云


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-09 22:51:10 評論於
In 2021, CD is 39.397, CC is 31.743
(0) 讚! | 血天谷云

作者: 龙鳞尚萍


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-09 19:37:39 評論於
Before Cancer Cell discovered cancer, you've got it wrong. I've noticed that articles in CD have been lower than CC in recent years, and this year in 2022, the score for CC is higher than CD
(0) 讚! | 龙鳞尚萍

作者: 血天谷云


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-09 17:09:54 評論於
The IF of CD has been higher than CC for several years, so please investigate it carefully
(0) 讚! | 血天谷云

作者: 血天谷云


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-05-26 22:09:32 評論於
Top journal! It is ranked ahead of cancer cell. Hope to complete the work in the second half of the year and give it a try for publication
(0) 讚! | 血天谷云

作者: 太山嘉懿


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-01-12 22:13:11 評論於
Your attitude is really good!
(0) 讚! | 太山嘉懿

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 20:06:42 評論於
The Importance of Exercise in Maintaining Overall Health
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 10:57:13 評論於
Make a list of the most important keywords; come up with a title that includes all the vocabulary; remove unnecessary/repetitive words and link the remaining words; rewrite the title after deleting non-essential information
(0) 讚! | 维尔娜菲茨杰拉德

作者: 平原文波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 16:58:23 評論於
Is there a trick to writing article titles?
(0) 讚! | 平原文波

作者: 北国博达


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 15:21:52 評論於
How to Write a Better Article Title?
(0) 讚! | 北国博达

作者: 法慧佳文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-08-04 16:23:35 評論於
Review speed: 1.0 | Submission hit rate: 5.0
Experience sharing: In the field of blood, I submitted a paper and it was rejected in one week. The reason was that some papers had already been published in this field before, and the level of innovation was lacking a bit. However, it was recommended to submit to Blood Cancer Discovery, a new journal under AACR, with top quality articles, but currently without impact factor. I eventually gave up on resubmitting. In short, there is little hope if there is a lack of innovation. The layout of the magazine is really beautiful, with exquisite articles on the front page
(0) 讚! | 法慧佳文

作者: 重阳文景


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-07-03 13:11:31 評論於
I have been following this magazine for a long time. The quality of the articles they publish is indeed very high. It is not easy for ordinary people to get published. To publish, you really need to have good ideas and conduct detailed research on the mechanism
(0) 讚! | 重阳文景

作者: 重阳文景


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-06-30 19:10:35 評論於
It is indeed a very classic magazine
(0) 讚! | 重阳文景

作者: Bevis Bart


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-05-18 14:45:50 評論於
Really like the layout of this magazine. It mostly features articles on current hot topics, making it difficult for niche studies to be published
(0) 讚! | Bevis Bart

作者: 重阳文景


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-05-09 13:46:59 評論於
I really want to publish a paper in this journal!!
There are only over 80 articles published in a year. It must be difficult to get accepted
(0) 讚! | 重阳文景

作者: 无击幻玉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-01-09 08:55:21 評論於
Only over 80 articles in a year, it must be difficult to pitch
(0) 讚! | 无击幻玉

作者: Emmanuel Katte


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-09-28 13:27:27 評論於
This magazine is too slow, it's been a month and still in submission status?
(0) 讚! | Emmanuel Katte

首頁    上一頁    1    2    下一頁    末頁  (頁
/2)

開始撰寫 [Cancer Discovery] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*